The TPM-01 delivery system has been shown to be capable of delivering a wide range of drugs that are up to 1,500 Daltons in size.  To date approximately 300 candidates have been identified as compatible with this technology.

“Proof of concept” for TPM-01 has been demonstrated in animal studies with atropine, oestradiol, testosterone, morphine, fentanyl and oxycodone. Phase I studies with the drug morphine have provided clinical support for the effectiveness of TPM-01 in delivering therapeutic plasma levels in humans.

Whilst the exact transport mechanism of TPM-01 is not yet fully characterised, in transdermal applications it appears that TPM-01 works by forming an association with certain drugs, and then (via a transport mechanism contained within the dermis) the associated TPM-01/drug is efficiently transported through the skin. Once the drug has been transported across the skin, it disassociates from TPM-01.

This efficient diffusion through skin creates a subcutaneous drug reservoir - and it is this pool that then allows for a sustained systemic delivery.